NGENLA 60 - Pfizer

The earliest use of Human Growth Hormone therapy began in 1958, relying on pituitary gland extractions from cadavers. While this method was effective for treating growth disorders in children, it was halted in 1985 when it was linked to Creutzfeldt-Jakob disease, a fatal neurological condition. That same year marked a major shift: Genentech released somatrem, the first synthetic HGH produced using recombinant DNA. Though it differed slightly from the body’s natural hormone, it led directly to somatropin, a bioidentical and safer version that remains the preferred option today.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about NGENLA 60 by Pfizer, consult with your doctor or healthcare professional.